Cullinan Therapeutics Inc (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company that develops oncology and immunology product candidates. The company generates no product revenue, operating instead as a research and development organization funded by equity raises and, as of a June 4, 2025 license agreement filed with the 10-K (accession 000119312526099362), a licensing arrangement with Chongqing Genrix Biopharmaceutical Co., Ltd. Cullinan relies on third-party contract manufacturers and contract research organizations to produce drug candidates and conduct clinical trials. The company has accumulated a deficit as of December 31, 2024, reflecting its pre-commercial status. Capital structure is weighted toward equity, with common stock issuances and pre-funded warrants disclosed in the FY2024 financial statements. No product has received marketing approval as of the filing date of March 10, 2026.

Revenue model

Pre-revenue clinical-stage model. Capital is raised through equity issuances, including common stock and pre-funded warrants. A license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd., dated June 4, 2025, represents a potential licensing revenue stream. No product sales revenue is disclosed in the FY2024 10-K.

Products and services

Clinical-stage product candidates in oncology and immunology. Specific product names and pipeline stage details are not supported by the provided filing excerpts.

Customers and end markets

Target end markets include physicians, patients, hospitals, and treatment centers, as referenced in the FY2024 10-K. No commercial customers exist as of the filing date. Market acceptance depends on third-party payor coverage, reimbursement, and pricing from government authorities.

Value-chain role

Drug developer positioned upstream of commercialization. Cullinan outsources manufacturing to third-party contract manufacturers and outsources clinical trial execution to contract research organizations. The company does not own manufacturing facilities.

Geographic exposure

Primary operations in the United States. Clinical trial subject data is also collected under EU GDPR jurisdiction, indicating some European clinical activity. No specific revenue by geography is disclosed in the provided excerpts.

Source: SEC 10-K, filed 2026-03-10

Industry: Biological Products, (No Diagnostic Substances) Peers: Adicet Bio Inc Agenus Inc Altimmune Inc Century Therapeutics Inc Inhibrx, Inc. Kezar Life Sciences Inc Nurix Therapeutics Inc Vanda Pharmaceuticals Inc Vera Therapeutics, Inc